Internal medicine

Medicine & Life Sciences

1. Melanoma 100%
2. pembrolizumab 70%
3. Belgium 64%
4. Coronavirus 62%
5. Dendritic Cells 56%
6. Ipilimumab 52%
7. HIV 48%
8. Therapeutics 46%
9. Nivolumab 44%
10. Clinical Trials, Phase I 40%
11. avelumab 39%
12. trametinib 34%
13. dabrafenib 33%
14. HIV-1 32%
15. Neoplasms 30%
16. Islets of Langerhans 29%
17. Glioblastoma 28%
18. Type 1 Diabetes Mellitus 28%
19. trimix 28%
20. Safety 27%
21. Myeloid Cells 26%
22. Phase II Clinical Trials 25%
23. T-Lymphocytes 25%
24. Survival 23%
25. Vaccines 23%
26. Tumor Burden 22%
27. Brugada Syndrome 22%
28. Immunotherapy 22%
29. Thyroid Gland 21%
30. Clinical Trials 20%
31. Axitinib 19%
32. Systematic Reviews 18%
33. Renal Replacement Therapy 18%
34. Fluorodeoxyglucose F18 18%
35. Messenger RNA 17%
36. Infection 17%
37. HIV Infections 17%
38. Lactams 17%
39. Mitogen-Activated Protein Kinase Kinases 17%
40. Hemofiltration 16%
41. Cohort Studies 15%
42. Standard of Care 15%
43. Anti-Bacterial Agents 15%
44. Recurrence 15%
45. Population 14%
46. Retrospective Studies 14%
47. Pharmaceutical Preparations 14%
48. Severe Acute Respiratory Syndrome 13%
49. Vaccination 13%
50. Cardiac Arrhythmias 13%
51. Pancreas 13%
52. Frailty 13%
53. Biomarkers 13%
54. Transplants 13%
55. Non-Small Cell Lung Carcinoma 12%
56. Neoplasm Metastasis 12%
57. Ventilator-Associated Pneumonia 12%
58. Familial Hypophosphatemic Rickets 12%
59. Antibodies 12%
60. Observational Studies 12%
61. Activities of Daily Living 12%
62. Tsunamis 12%
63. Fever 12%
64. Programmed Cell Death 1 Receptor 12%
65. Blocking Antibodies 12%
66. Liver 12%
67. Injections 12%
68. Skin 11%
69. dicarboxydine 11%
70. Peptides 11%
71. Cytokines 11%
72. Fatigue 11%
73. Incidence 11%
74. Immunologic Monitoring 11%
75. Progression-Free Survival 11%
76. Autoimmunity 11%
77. Atrial Fibrillation 10%
78. Lymphoma 10%
79. Viruses 10%
80. Cell Death 10%
81. Delivery of Health Care 10%
82. Echocardiography 10%
83. SARS Virus 10%
84. AIDS Vaccines 10%
85. Hypophysitis 10%
86. Insulin 10%
87. Parathyroid Neoplasms 10%
88. Serum 10%
89. Adrenocorticotropic Hormone 10%
90. Omentum 9%
91. Critical Illness 9%
92. Pituitary Neoplasms 9%
93. Public Health 9%
94. Meta-Analysis 9%
95. Hypertension 9%
96. Monoclonal Antibodies 9%
97. Delirium 9%
98. IGL-1 solution 9%
99. Autoantibodies 9%
100. Survivors 9%